NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · Japan
Takeda Pharmaceutical Co ADR is a large cap company (market value between $10 billion and $200 billion) in the Drug Manufacturers - Specialty & Generic industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Takeda Pharmaceutical Co ADR stock.
Overvalued: intrinsic value $3.53 per share, market price $20.91, margin of safety -492.8% (as of 2026-10-30).
Discounting its cash flows at 8.9% (average of 3 methods) values the shares at $3.53; the price of $20.91 is 493% above that value, and 76% of that value comes from beyond year five.
Leak Score: 26/100 on 11 of 12 signals (On Watch).
All 84 Drug Manufacturers - Specialty & Generic stocks
32 more in this industry show a wider margin of safety.
TAK is overvalued (as of the 2026-10-30 close). Discounting its cash flows at 8.9% (average of 3 methods) values the shares at $3.53; the price of $20.91 is 493% above that value, and 76% of that value comes from beyond year five.
$3.53 per share (as of the 2026-10-30 close), against a market price of $20.91. That is a margin of safety of -492.8%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price needs faster growth than we project for any company. It is betting on an exception. Yearly sales growth the price needs: 49.1%. Yearly sales decline it has shown: 1.5%.
26 out of 100, which we rate "On Watch", on 11 of 12 value investing signals.